Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
Date:5/16/2013

SAN FRANCISCO, May 16, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin , is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 21, 2013 at 10:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted in the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until June 22, 2013.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers. I
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... , NEW YORK, Nov. 17 ... research report is available in its catalogue. ... Biomaterials 2009 (15 Countries) , ... 2008, the combined European biomaterial market was ...
... , BEIJING, ... developer and provider of vaccines in China, announced today that ... Administration,for Panflu.1, the Company,s H1N1 vaccine. The population has been ... for PANFLU.1 was extended to,one year from six months. , ...
Cached Medicine Technology:Reportlinker Adds European Markets for Orthopedic Biomaterials 2009 (15 Countries) 2Sinovac's PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population 2
(Date:7/9/2014)... almost all types of cancer sends the protein factories ... a tumour,s uncontrolled growth, new research suggests. , Scientists ... molecular trigger responsible for ratcheting up activity of the ... the building blocks cancer cells need to keep growing. ... SREBP, controls the flow of messages to the endoplasmic ...
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
(Date:7/9/2014)... BostonPractices used in policing injection drug users in ... mortality. , A study, conducted by researchers ... Health, in collaboration with St. Petersburg Pavlov State ... had on the health outcomes of a cohort ... use. , Those who were arrested by police ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... (HealthDay News) -- Men with high amounts of the controversial ... have impaired semen quality, a new study of factory workers ... National Institute of Occupational Safety and Health, found high urine ... drop in sperm concentration, overall sperm count, sperm vitality and ...
... Wisconsin are conducting the KAST clinical trial at ... of a new vertebral augmentation treatment (Kiva) for ... Sean Tutton, M.D, associate professor ... is principal interventional radiology investigator for this multi-institutional, ...
... Reporter , THURSDAY, Oct. 28 (HealthDay News) -- Better treatments are ... AIDS-causing virus takes a toll that will challenge the health care ... HIV-positive men and women ages 50 and older living in New ... much higher rate than others their age without HIV. And ...
... in everything from laws about using your cell phone while ... pass on fourth down come to Austin on November 7, ... people who use math for a living but also problem ... of the Institute for Operations Research and the Management Sciences ...
... to different prescription drug plans because Part D reimbursements ... the actual costs incurred, according to a study released ... describes how a system designed to encourage competition and ... led companies to raise their premiums in an effort ...
... HealthDay Reporter , THURSDAY, Oct. 28 (HealthDay News) -- ... might help protect women from breast cancer, a new, ... "We found no overall association between green tea intake ... who have habitually drunk green tea," said lead researcher ...
Cached Medicine News:Health News:Plastics Chemical BPA Tied to Poor Sperm Quality 2Health News:Plastics Chemical BPA Tied to Poor Sperm Quality 3Health News:National research study to assess new treatment for painful vertebral fractures 2Health News:More Older Americans Living With HIV 2Health News:More Older Americans Living With HIV 3Health News:4,000 numbers crunchers count on Austin 2Health News:Study identifies flaws in Medicare prescription drug program 2Health News:Study Finds Green Tea Offers No Protection From Breast Cancer 2
Sabre 180, 230V, 50Hz is a powerful niche generator....
High performance capabilities in a multipurpose generator, blended cut modes, simultaneous independent coagulation, low voltage coagulation, valleylab REM safety substantially reduces the risk of pat...
Lorgnette pinhole occluder...
Black multi-pinhole occluder...
Medicine Products: